Conestat Alfa

Summary

Conestat Alfa (CHEMBL2108350) is an approved protein (ATC B06AC04); indicated across 7 conditions including hereditary angioedema and acute kidney injury.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: B06AC04
• Indications: 7 conditions
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108350
Name	Conestat Alfa
Type	Protein
Max phase	4
ATC	B06AC04

Also known as: C1 esterase inhibitor, Complement c1 esterase inhibitor, Conestat alfa, Recombinant human c1 inhibitor, Rhucin, Ruconest, CONESTAT ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hereditary angioedema	4	MONDO:0019623	MONDO:0019623
acute kidney injury	2	MONDO:0002492	HP:0001919
hereditary disease	2	MONDO:0003847	EFO:0000508
graft versus host disease	2	MONDO:0013730	EFO:0004599
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE2	6
PHASE3	3
PHASE2/PHASE3	2
PHASE1/PHASE2	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06690047	PHASE4	COMPLETED	Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)
NCT06679426	PHASE3	NOT_YET_RECRUITING	Safety and Efficacy of Conestat Alfa for ACE-Induced Angioedema
NCT00168103	PHASE2/PHASE3	COMPLETED	Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks
NCT00225147	PHASE2/PHASE3	COMPLETED	Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
NCT00262301	PHASE3	COMPLETED	Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
NCT00292981	PHASE3	COMPLETED	C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)
NCT00851409	PHASE2	COMPLETED	A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration
NCT01134510	PHASE1/PHASE2	COMPLETED	Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection
NCT02134314	PHASE1/PHASE2	COMPLETED	C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
NCT02247739	PHASE2	COMPLETED	A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor
NCT02869347	PHASE2	COMPLETED	Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects
NCT04414631	PHASE2	TERMINATED	Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
NCT04530136	PHASE2	COMPLETED	Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
NCT04705831	PHASE2	COMPLETED	Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).